J. Goldman & Co’s Apogee Therapeutics APGE Stock Holding History

J. Goldman & Co’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$869K	–	456
2025 Q2	$869K	Buy	+20,000	New	+$761K	0.02%	345

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

J. Goldman & Co's APGE Position: Q1 2026 in Review

J. Goldman & Co sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 3,466 shares — an estimated $262K sold.

J. Goldman & Co first reported a position in APGE in Q2 2025 and held it in 3 quarters. The position peaked at $2.49M in Q3 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

J. Goldman & Co reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 3,466 Apogee Therapeutics shares in Q1 2026, an estimated $262K.
J. Goldman & Co first reported a position in Apogee Therapeutics in Q2 2025 and held it in 3 quarters.
J. Goldman & Co's Apogee Therapeutics position peaked at $2.49M in Q3 2025.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.